Cioteronel
Appearance
![]() | |
Clinical data | |
---|---|
Other names | CPC-10997; Cyoctol; X-Andron |
Routes of administration | By mouth, topical |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H28O2 |
Molar mass | 252.398 g·mol−1 |
3D model (JSmol) | |
| |
|
Cioteronel (INN , USAN ) (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.[1][2][3] It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.[3][4]
See also
References
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.
- ^ Lednicer, Daniel (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (|name-list-style=
suggested) (help) - ^ a b Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543784.14.11.1359. PMID 16255676.
- ^ "Cioteronel". Adis Insight. Springer Nature Switzerland AG.